Dissection of the Neonatal Fc Receptor (FcRn)-Albumin Interface Using Mutagenesis and Anti-FcRn Albumin-blocking Antibodies

Albumin is the most abundant protein in blood and plays a pivotal role as a multitransporter of a wide range of molecules such as fatty acids, metabolites, hormones, and toxins. In addition, it binds a variety of drugs. Its role as distributor is supported by its extraordinary serum half-life of 3 w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of biological chemistry 2014-06, Vol.289 (24), p.17228-17239
Hauptverfasser: Sand, Kine Marita Knudsen, Dalhus, Bjørn, Christianson, Gregory J., Bern, Malin, Foss, Stian, Cameron, Jason, Sleep, Darrell, Bjørås, Magnar, Roopenian, Derry C., Sandlie, Inger, Andersen, Jan Terje
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 17239
container_issue 24
container_start_page 17228
container_title The Journal of biological chemistry
container_volume 289
creator Sand, Kine Marita Knudsen
Dalhus, Bjørn
Christianson, Gregory J.
Bern, Malin
Foss, Stian
Cameron, Jason
Sleep, Darrell
Bjørås, Magnar
Roopenian, Derry C.
Sandlie, Inger
Andersen, Jan Terje
description Albumin is the most abundant protein in blood and plays a pivotal role as a multitransporter of a wide range of molecules such as fatty acids, metabolites, hormones, and toxins. In addition, it binds a variety of drugs. Its role as distributor is supported by its extraordinary serum half-life of 3 weeks. This is related to its size and binding to the cellular receptor FcRn, which rescues albumin from intracellular degradation. Furthermore, the long half-life has fostered a great and increasing interest in utilization of albumin as a carrier of protein therapeutics and chemical drugs. However, to fully understand how FcRn acts as a regulator of albumin homeostasis and to take advantage of the FcRn-albumin interaction in drug design, the interaction interface needs to be dissected. Here, we used a panel of monoclonal antibodies directed towards human FcRn in combination with site-directed mutagenesis and structural modeling to unmask the binding sites for albumin blocking antibodies and albumin on the receptor, which revealed that the interaction is not only strictly pH-dependent, but predominantly hydrophobic in nature. Specifically, we provide mechanistic evidence for a crucial role of a cluster of conserved tryptophan residues that expose a pH-sensitive loop of FcRn, and identify structural differences in proximity to these hot spot residues that explain divergent cross-species binding properties of FcRn. Our findings expand our knowledge of how FcRn is controlling albumin homeostasis at a molecular level, which will guide design and engineering of novel albumin variants with altered transport properties. Background: Albumin has a long serum half-life, which is regulated by FcRn. Results: A cluster of conserved tryptophan residues of FcRn is required for binding to albumin and anti-FcRn albumin blocking antibodies. Conclusion: The FcRn-albumin interaction is pH-dependent but hydrophobic in nature. Significance: This study provides mechanistic insight into how FcRn binds albumin and regulates its long half-life.
doi_str_mv 10.1074/jbc.M113.522565
format Article
fullrecord <record><control><sourceid>pubmed_crist</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4059163</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021925820406921</els_id><sourcerecordid>24764301</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-13a5a0846cdfe9d2dd53a8da7a2867874aede55220ee56b7c3ade0912a9904883</originalsourceid><addsrcrecordid>eNp1kc9rFDEUx4Modq2evWmO9jDbJJPMj4uw1K4WWoViwVt4k7zZps4mS5ItiP-8GbYtejCXd3if9yV8P4S85WzJWStP7wazvOK8XiohVKOekQVnXV3Viv94ThaMCV71QnVH5FVKd6w82fOX5EjItpE14wvy-5NLCU12wdMw0nyL9CsGDxkmujb0Gg3ucoj0w9pc-5NqNQ37rfP0wmeMIxikN8n5Db3aZ9igx-QSBW_pymdXzSf04aIapmB-zui8GoJ1mF6TFyNMCd88zGNysz7_fvaluvz2-eJsdVkZ2bS54jUoYJ1sjB2xt8JaVUNnoQXRNW3XSkCLqhTAEFUztKYGi6znAvqeya6rj8nHQ-5uP2zRGvQ5wqR30W0h_tIBnP53492t3oR7LZnqeVOXgPeHABNdys5rHyLo0rQSWknF2kKcPhIhpYjjUzpnejaliyk9m9IHU-Xi3d-feuIf1RSgPwBYqrl3GHUyDr1B62IRpm1w_w3_A-4wo0A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Dissection of the Neonatal Fc Receptor (FcRn)-Albumin Interface Using Mutagenesis and Anti-FcRn Albumin-blocking Antibodies</title><source>MEDLINE</source><source>NORA - Norwegian Open Research Archives</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Sand, Kine Marita Knudsen ; Dalhus, Bjørn ; Christianson, Gregory J. ; Bern, Malin ; Foss, Stian ; Cameron, Jason ; Sleep, Darrell ; Bjørås, Magnar ; Roopenian, Derry C. ; Sandlie, Inger ; Andersen, Jan Terje</creator><creatorcontrib>Sand, Kine Marita Knudsen ; Dalhus, Bjørn ; Christianson, Gregory J. ; Bern, Malin ; Foss, Stian ; Cameron, Jason ; Sleep, Darrell ; Bjørås, Magnar ; Roopenian, Derry C. ; Sandlie, Inger ; Andersen, Jan Terje</creatorcontrib><description>Albumin is the most abundant protein in blood and plays a pivotal role as a multitransporter of a wide range of molecules such as fatty acids, metabolites, hormones, and toxins. In addition, it binds a variety of drugs. Its role as distributor is supported by its extraordinary serum half-life of 3 weeks. This is related to its size and binding to the cellular receptor FcRn, which rescues albumin from intracellular degradation. Furthermore, the long half-life has fostered a great and increasing interest in utilization of albumin as a carrier of protein therapeutics and chemical drugs. However, to fully understand how FcRn acts as a regulator of albumin homeostasis and to take advantage of the FcRn-albumin interaction in drug design, the interaction interface needs to be dissected. Here, we used a panel of monoclonal antibodies directed towards human FcRn in combination with site-directed mutagenesis and structural modeling to unmask the binding sites for albumin blocking antibodies and albumin on the receptor, which revealed that the interaction is not only strictly pH-dependent, but predominantly hydrophobic in nature. Specifically, we provide mechanistic evidence for a crucial role of a cluster of conserved tryptophan residues that expose a pH-sensitive loop of FcRn, and identify structural differences in proximity to these hot spot residues that explain divergent cross-species binding properties of FcRn. Our findings expand our knowledge of how FcRn is controlling albumin homeostasis at a molecular level, which will guide design and engineering of novel albumin variants with altered transport properties. Background: Albumin has a long serum half-life, which is regulated by FcRn. Results: A cluster of conserved tryptophan residues of FcRn is required for binding to albumin and anti-FcRn albumin blocking antibodies. Conclusion: The FcRn-albumin interaction is pH-dependent but hydrophobic in nature. Significance: This study provides mechanistic insight into how FcRn binds albumin and regulates its long half-life.</description><identifier>ISSN: 0021-9258</identifier><identifier>EISSN: 1083-351X</identifier><identifier>DOI: 10.1074/jbc.M113.522565</identifier><identifier>PMID: 24764301</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Albumin ; Albumins - metabolism ; Amino Acid Sequence ; Antibodies, Blocking - immunology ; Antibodies, Monoclonal - immunology ; Antibody ; Binding Sites ; Biodegradation ; Bioengineering ; Fc Receptor ; FcRn ; Half-life ; Histocompatibility Antigens Class I - chemistry ; Histocompatibility Antigens Class I - genetics ; Histocompatibility Antigens Class I - immunology ; Histocompatibility Antigens Class I - metabolism ; Humans ; Hydrogen-Ion Concentration ; Hydrophobic ; Hydrophobic and Hydrophilic Interactions ; Molecular Sequence Data ; Mutagenesis, Site-Directed ; pH Regulation ; Protein Binding ; Protein Structure and Folding ; Receptors, Fc - chemistry ; Receptors, Fc - genetics ; Receptors, Fc - immunology ; Receptors, Fc - metabolism</subject><ispartof>The Journal of biological chemistry, 2014-06, Vol.289 (24), p.17228-17239</ispartof><rights>2014 © 2014 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.</rights><rights>2014 by The American Society for Biochemistry and Molecular Biology, Inc.</rights><rights>info:eu-repo/semantics/openAccess</rights><rights>2014 by The American Society for Biochemistry and Molecular Biology, Inc. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-13a5a0846cdfe9d2dd53a8da7a2867874aede55220ee56b7c3ade0912a9904883</citedby><cites>FETCH-LOGICAL-c467t-13a5a0846cdfe9d2dd53a8da7a2867874aede55220ee56b7c3ade0912a9904883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059163/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059163/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,26544,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24764301$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sand, Kine Marita Knudsen</creatorcontrib><creatorcontrib>Dalhus, Bjørn</creatorcontrib><creatorcontrib>Christianson, Gregory J.</creatorcontrib><creatorcontrib>Bern, Malin</creatorcontrib><creatorcontrib>Foss, Stian</creatorcontrib><creatorcontrib>Cameron, Jason</creatorcontrib><creatorcontrib>Sleep, Darrell</creatorcontrib><creatorcontrib>Bjørås, Magnar</creatorcontrib><creatorcontrib>Roopenian, Derry C.</creatorcontrib><creatorcontrib>Sandlie, Inger</creatorcontrib><creatorcontrib>Andersen, Jan Terje</creatorcontrib><title>Dissection of the Neonatal Fc Receptor (FcRn)-Albumin Interface Using Mutagenesis and Anti-FcRn Albumin-blocking Antibodies</title><title>The Journal of biological chemistry</title><addtitle>J Biol Chem</addtitle><description>Albumin is the most abundant protein in blood and plays a pivotal role as a multitransporter of a wide range of molecules such as fatty acids, metabolites, hormones, and toxins. In addition, it binds a variety of drugs. Its role as distributor is supported by its extraordinary serum half-life of 3 weeks. This is related to its size and binding to the cellular receptor FcRn, which rescues albumin from intracellular degradation. Furthermore, the long half-life has fostered a great and increasing interest in utilization of albumin as a carrier of protein therapeutics and chemical drugs. However, to fully understand how FcRn acts as a regulator of albumin homeostasis and to take advantage of the FcRn-albumin interaction in drug design, the interaction interface needs to be dissected. Here, we used a panel of monoclonal antibodies directed towards human FcRn in combination with site-directed mutagenesis and structural modeling to unmask the binding sites for albumin blocking antibodies and albumin on the receptor, which revealed that the interaction is not only strictly pH-dependent, but predominantly hydrophobic in nature. Specifically, we provide mechanistic evidence for a crucial role of a cluster of conserved tryptophan residues that expose a pH-sensitive loop of FcRn, and identify structural differences in proximity to these hot spot residues that explain divergent cross-species binding properties of FcRn. Our findings expand our knowledge of how FcRn is controlling albumin homeostasis at a molecular level, which will guide design and engineering of novel albumin variants with altered transport properties. Background: Albumin has a long serum half-life, which is regulated by FcRn. Results: A cluster of conserved tryptophan residues of FcRn is required for binding to albumin and anti-FcRn albumin blocking antibodies. Conclusion: The FcRn-albumin interaction is pH-dependent but hydrophobic in nature. Significance: This study provides mechanistic insight into how FcRn binds albumin and regulates its long half-life.</description><subject>Albumin</subject><subject>Albumins - metabolism</subject><subject>Amino Acid Sequence</subject><subject>Antibodies, Blocking - immunology</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibody</subject><subject>Binding Sites</subject><subject>Biodegradation</subject><subject>Bioengineering</subject><subject>Fc Receptor</subject><subject>FcRn</subject><subject>Half-life</subject><subject>Histocompatibility Antigens Class I - chemistry</subject><subject>Histocompatibility Antigens Class I - genetics</subject><subject>Histocompatibility Antigens Class I - immunology</subject><subject>Histocompatibility Antigens Class I - metabolism</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Hydrophobic</subject><subject>Hydrophobic and Hydrophilic Interactions</subject><subject>Molecular Sequence Data</subject><subject>Mutagenesis, Site-Directed</subject><subject>pH Regulation</subject><subject>Protein Binding</subject><subject>Protein Structure and Folding</subject><subject>Receptors, Fc - chemistry</subject><subject>Receptors, Fc - genetics</subject><subject>Receptors, Fc - immunology</subject><subject>Receptors, Fc - metabolism</subject><issn>0021-9258</issn><issn>1083-351X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>3HK</sourceid><recordid>eNp1kc9rFDEUx4Modq2evWmO9jDbJJPMj4uw1K4WWoViwVt4k7zZps4mS5ItiP-8GbYtejCXd3if9yV8P4S85WzJWStP7wazvOK8XiohVKOekQVnXV3Viv94ThaMCV71QnVH5FVKd6w82fOX5EjItpE14wvy-5NLCU12wdMw0nyL9CsGDxkmujb0Gg3ucoj0w9pc-5NqNQ37rfP0wmeMIxikN8n5Db3aZ9igx-QSBW_pymdXzSf04aIapmB-zui8GoJ1mF6TFyNMCd88zGNysz7_fvaluvz2-eJsdVkZ2bS54jUoYJ1sjB2xt8JaVUNnoQXRNW3XSkCLqhTAEFUztKYGi6znAvqeya6rj8nHQ-5uP2zRGvQ5wqR30W0h_tIBnP53492t3oR7LZnqeVOXgPeHABNdys5rHyLo0rQSWknF2kKcPhIhpYjjUzpnejaliyk9m9IHU-Xi3d-feuIf1RSgPwBYqrl3GHUyDr1B62IRpm1w_w3_A-4wo0A</recordid><startdate>20140613</startdate><enddate>20140613</enddate><creator>Sand, Kine Marita Knudsen</creator><creator>Dalhus, Bjørn</creator><creator>Christianson, Gregory J.</creator><creator>Bern, Malin</creator><creator>Foss, Stian</creator><creator>Cameron, Jason</creator><creator>Sleep, Darrell</creator><creator>Bjørås, Magnar</creator><creator>Roopenian, Derry C.</creator><creator>Sandlie, Inger</creator><creator>Andersen, Jan Terje</creator><general>Elsevier Inc</general><general>American Society for Biochemistry and Molecular Biology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3HK</scope><scope>5PM</scope></search><sort><creationdate>20140613</creationdate><title>Dissection of the Neonatal Fc Receptor (FcRn)-Albumin Interface Using Mutagenesis and Anti-FcRn Albumin-blocking Antibodies</title><author>Sand, Kine Marita Knudsen ; Dalhus, Bjørn ; Christianson, Gregory J. ; Bern, Malin ; Foss, Stian ; Cameron, Jason ; Sleep, Darrell ; Bjørås, Magnar ; Roopenian, Derry C. ; Sandlie, Inger ; Andersen, Jan Terje</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-13a5a0846cdfe9d2dd53a8da7a2867874aede55220ee56b7c3ade0912a9904883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Albumin</topic><topic>Albumins - metabolism</topic><topic>Amino Acid Sequence</topic><topic>Antibodies, Blocking - immunology</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibody</topic><topic>Binding Sites</topic><topic>Biodegradation</topic><topic>Bioengineering</topic><topic>Fc Receptor</topic><topic>FcRn</topic><topic>Half-life</topic><topic>Histocompatibility Antigens Class I - chemistry</topic><topic>Histocompatibility Antigens Class I - genetics</topic><topic>Histocompatibility Antigens Class I - immunology</topic><topic>Histocompatibility Antigens Class I - metabolism</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Hydrophobic</topic><topic>Hydrophobic and Hydrophilic Interactions</topic><topic>Molecular Sequence Data</topic><topic>Mutagenesis, Site-Directed</topic><topic>pH Regulation</topic><topic>Protein Binding</topic><topic>Protein Structure and Folding</topic><topic>Receptors, Fc - chemistry</topic><topic>Receptors, Fc - genetics</topic><topic>Receptors, Fc - immunology</topic><topic>Receptors, Fc - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sand, Kine Marita Knudsen</creatorcontrib><creatorcontrib>Dalhus, Bjørn</creatorcontrib><creatorcontrib>Christianson, Gregory J.</creatorcontrib><creatorcontrib>Bern, Malin</creatorcontrib><creatorcontrib>Foss, Stian</creatorcontrib><creatorcontrib>Cameron, Jason</creatorcontrib><creatorcontrib>Sleep, Darrell</creatorcontrib><creatorcontrib>Bjørås, Magnar</creatorcontrib><creatorcontrib>Roopenian, Derry C.</creatorcontrib><creatorcontrib>Sandlie, Inger</creatorcontrib><creatorcontrib>Andersen, Jan Terje</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>NORA - Norwegian Open Research Archives</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of biological chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sand, Kine Marita Knudsen</au><au>Dalhus, Bjørn</au><au>Christianson, Gregory J.</au><au>Bern, Malin</au><au>Foss, Stian</au><au>Cameron, Jason</au><au>Sleep, Darrell</au><au>Bjørås, Magnar</au><au>Roopenian, Derry C.</au><au>Sandlie, Inger</au><au>Andersen, Jan Terje</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dissection of the Neonatal Fc Receptor (FcRn)-Albumin Interface Using Mutagenesis and Anti-FcRn Albumin-blocking Antibodies</atitle><jtitle>The Journal of biological chemistry</jtitle><addtitle>J Biol Chem</addtitle><date>2014-06-13</date><risdate>2014</risdate><volume>289</volume><issue>24</issue><spage>17228</spage><epage>17239</epage><pages>17228-17239</pages><issn>0021-9258</issn><eissn>1083-351X</eissn><abstract>Albumin is the most abundant protein in blood and plays a pivotal role as a multitransporter of a wide range of molecules such as fatty acids, metabolites, hormones, and toxins. In addition, it binds a variety of drugs. Its role as distributor is supported by its extraordinary serum half-life of 3 weeks. This is related to its size and binding to the cellular receptor FcRn, which rescues albumin from intracellular degradation. Furthermore, the long half-life has fostered a great and increasing interest in utilization of albumin as a carrier of protein therapeutics and chemical drugs. However, to fully understand how FcRn acts as a regulator of albumin homeostasis and to take advantage of the FcRn-albumin interaction in drug design, the interaction interface needs to be dissected. Here, we used a panel of monoclonal antibodies directed towards human FcRn in combination with site-directed mutagenesis and structural modeling to unmask the binding sites for albumin blocking antibodies and albumin on the receptor, which revealed that the interaction is not only strictly pH-dependent, but predominantly hydrophobic in nature. Specifically, we provide mechanistic evidence for a crucial role of a cluster of conserved tryptophan residues that expose a pH-sensitive loop of FcRn, and identify structural differences in proximity to these hot spot residues that explain divergent cross-species binding properties of FcRn. Our findings expand our knowledge of how FcRn is controlling albumin homeostasis at a molecular level, which will guide design and engineering of novel albumin variants with altered transport properties. Background: Albumin has a long serum half-life, which is regulated by FcRn. Results: A cluster of conserved tryptophan residues of FcRn is required for binding to albumin and anti-FcRn albumin blocking antibodies. Conclusion: The FcRn-albumin interaction is pH-dependent but hydrophobic in nature. Significance: This study provides mechanistic insight into how FcRn binds albumin and regulates its long half-life.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24764301</pmid><doi>10.1074/jbc.M113.522565</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9258
ispartof The Journal of biological chemistry, 2014-06, Vol.289 (24), p.17228-17239
issn 0021-9258
1083-351X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4059163
source MEDLINE; NORA - Norwegian Open Research Archives; PubMed Central; Alma/SFX Local Collection; EZB Electronic Journals Library
subjects Albumin
Albumins - metabolism
Amino Acid Sequence
Antibodies, Blocking - immunology
Antibodies, Monoclonal - immunology
Antibody
Binding Sites
Biodegradation
Bioengineering
Fc Receptor
FcRn
Half-life
Histocompatibility Antigens Class I - chemistry
Histocompatibility Antigens Class I - genetics
Histocompatibility Antigens Class I - immunology
Histocompatibility Antigens Class I - metabolism
Humans
Hydrogen-Ion Concentration
Hydrophobic
Hydrophobic and Hydrophilic Interactions
Molecular Sequence Data
Mutagenesis, Site-Directed
pH Regulation
Protein Binding
Protein Structure and Folding
Receptors, Fc - chemistry
Receptors, Fc - genetics
Receptors, Fc - immunology
Receptors, Fc - metabolism
title Dissection of the Neonatal Fc Receptor (FcRn)-Albumin Interface Using Mutagenesis and Anti-FcRn Albumin-blocking Antibodies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T18%3A21%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_crist&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dissection%20of%20the%20Neonatal%20Fc%20Receptor%20(FcRn)-Albumin%20Interface%20Using%20Mutagenesis%20and%20Anti-FcRn%20Albumin-blocking%20Antibodies&rft.jtitle=The%20Journal%20of%20biological%20chemistry&rft.au=Sand,%20Kine%20Marita%20Knudsen&rft.date=2014-06-13&rft.volume=289&rft.issue=24&rft.spage=17228&rft.epage=17239&rft.pages=17228-17239&rft.issn=0021-9258&rft.eissn=1083-351X&rft_id=info:doi/10.1074/jbc.M113.522565&rft_dat=%3Cpubmed_crist%3E24764301%3C/pubmed_crist%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/24764301&rft_els_id=S0021925820406921&rfr_iscdi=true